https://orcid.org/0000-0002-0807-7139
Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Maryam A. Adas, Edward Alveyn, Emma Cook, Mrinalini Dey, James B Galloway & Katie Bechman. (2022) The infection risks of JAK inhibition. Expert Review of Clinical Immunology 18:3, pages 253-261.
Read now
Read now
Articles from other publishers (25)
K. Sunil Chowdary & A. A. Napoleon. (2023) Utilizing Quality by Design to Develop and Evaluate Extended-Release Upadacitinib Tablets Incorporating a Biosynthesized Polymer. Journal of Pharmaceutical Innovation.
Crossref
Crossref
Maryam Mehrpooya, Mahnam Majmasanaye, Fatemeh Faramarzi, Azadeh Eshraghi & Foroozan Faress. (2023) Investigation of the Effect of Oral Selenium on the Reduction of Clinical Symptoms and Joint Pain in Patients With Rheumatoid Arthritis in the Iranian Population. The Journal of Clinical Pharmacology.
Crossref
Crossref
Roy Fleischmann, Jeffrey R Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt & Gerd Burmester. (2023) Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Annals of the Rheumatic Diseases, pages ard-2023-223916.
Crossref
Crossref
Julian Laux, Mariella Martorelli, Nadja Späth, Florian Maier, Michael Burnet & Stefan A. Laufer. (2023) Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio. ACS Pharmacology & Translational Science 6:6, pages 892-906.
Crossref
Crossref
Rishika Chugh, Manuel B Braga-Neto, Thomas W Fredrick, Guilherme P Ramos, Jonathan Terdiman, Najwa El-Nachef, Edward V Loftus, Uma Mahadevan & Sunanda V Kane. (2023) Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease. Journal of Crohn's and Colitis 17:4, pages 504-512.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao & Yi Zhun Zhu. (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Erumalla Venkata Nagaraju. (2023) In-silico Prediction of Maximum Binding Affinity of Disease-Modifying Antirheumatic Drugs with Homo sapiens Acrosomal Protein SP-10. International Journal of Pharmaceutical Research And Allied Sciences 12:1, pages 59-65.
Crossref
Crossref
Kenneth Ernest-Suarez & Remo Panaccione. (2023) Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. Therapeutic Advances in Gastroenterology 16, pages 175628482311582.
Crossref
Crossref
Zhenwu Yang, Yujia Tian, Yue Kong, Yushan Zhu & Aixia Yan. (2022) Classification of JAK1 Inhibitors and SAR Research by Machine Learning Methods. Artificial Intelligence in the Life Sciences 2, pages 100039.
Crossref
Crossref
Martin Bergman, Maya H. Buch, Yoshiya Tanaka, Gustavo Citera, Sami Bahlas, Ernest Wong, Yanna Song, Patrick Zueger, Mira Ali & Vibeke Strand. (2022) Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatology and Therapy 9:6, pages 1517-1529.
Crossref
Crossref
E. Yu. Loginova & T. V. Korotaeva. (2022) Janus kinase inhibitors in the treatment of psoriatic arthritis. Modern Rheumatology Journal 16:1, pages 7-13.
Crossref
Crossref
Kevin L Winthrop, Peter Nash, Kunihiro Yamaoka, Eduardo Mysler, Nasser Khan, Heidi S Camp, Yanna Song, Jessica L Suboticki & Jeffrey R Curtis. (2022) Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Annals of the Rheumatic Diseases 81:2, pages 206-213.
Crossref
Crossref
Jens Martens-Lobenhoffer, Stylianos Tomaras, Eugen Feist & Stefanie M. Bode-Böger. (2022) Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of Chromatography B 1188, pages 123076.
Crossref
Crossref
Xiaofeng Zeng, Dongbao Zhao, Sebastiao C. Radominski, Mauro Keiserman, Chang K. Lee, Sebastian Meerwein, Jeffrey Enejosa, Yunxia Sui, Mohamed‐Eslam F. Mohamed & Won Park. (2021) Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. International Journal of Rheumatic Diseases 24:12, pages 1530-1539.
Crossref
Crossref
V. N. Amirjanova, A. E. Karateev, E. Y. Pogozheva, A. A. Baranov, V. I. Mazurov, R. R. Samigullina, O. N. Anoshenkova, N. A. Lapkina, T. Yu. Grineva, E. L. Nasonov & A. M. Lila. (2021) The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”). Rheumatology Science and Practice 59:5, pages 571-577.
Crossref
Crossref
Madina Sarsenova, Assel Issabekova, Saule Abisheva, Kristina Rutskaya-Moroshan, Vyacheslav Ogay & Arman Saparov. (2021) Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. International Journal of Molecular Sciences 22:21, pages 11592.
Crossref
Crossref
Huiyan Zhen, Xinxin Zhang, Lei Zhang, Mingming Zhou, Liangliang Lu, Lihong Wu, N a He, Juan Wang, Rui Li & Yan Guo. (2021) SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling. Acta Biochimica et Biophysica Sinica 53:8, pages 1098-1105.
Crossref
Crossref
Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, Nasser Khan, Nobuhito Sasaki, Masayoshi Harigai, Yanna Song, Ying Zhang & Tsutomu Takeuchi. (2021) The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety 44:6, pages 711-722.
Crossref
Crossref
Roy M Fleischmann, Ricardo Blanco, Stephen Hall, Glen T D Thomson, Filip E Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi & In-Ho Song. (2021) Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 80:4, pages 432-439.
Crossref
Crossref
Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa & Gerd R Burmester. (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases 80:3, pages 304-311.
Crossref
Crossref
Xing-Cheng Shao, Zhen-Hua Chen, Shuang-Shuang Liu, Fei Wu, Hong-Yan Mu, Wen-Hui Wei, Yi Feng, Jian-Ping Zuo, Ji-Quan Zhang, Shi-Jun He & Wei-Min Zhao. (2021) Minor immunosuppressive spiroorthoester group-containing pregnane glycosides from the root barks of Periploca sepium. Bioorganic Chemistry 108, pages 104641.
Crossref
Crossref
Elvira Favoino, Marcella Prete, Giacomo Catacchio, Piero Ruscitti, Luca Navarini, Roberto Giacomelli & Federico Perosa. (2021) Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. Autoimmunity Reviews 20:3, pages 102750.
Crossref
Crossref
Ali Berkant Avci, Eugen Feist & Gerd Rüdiger Burmester. (2021) The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110476.
Crossref
Crossref
E. L. Nasonov & A. M. Lila. (2020) The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Rheumatology Science and Practice 58:5, pages 532-543.
Crossref
Crossref